08-MAY-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3993 366 186 100 26 6 02/06/2019 473 184
Screened at PD     1485 221 126 75 18 4      
Pre-Screened prior to PD     2487 128 52 23 8 2      
Treatment-naive     21 17 8 2 0 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     532 29 14 10 2 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2170 282 159 88 27 5      
Screened at PD     1252 214 128 75 22 3      
Pre-Screened prior to PD     840 49 19 9 5 2      
Treatment-naive     21 17 10 3 0 0      
After PD on a Lung_MAP Sub-Study     57 2 2 1 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     369 246 138 80 27 5      
S1900G     35 5 3 1 0 0      
S1900J     18 7 4 3 0 0      
S1900K     38 24 14 4 0 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     620 117 74 38 8 0      
Initial sub-study registrations     608 117 74 38 8 0      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 92 92 59 33 7 0 05/22/2025 350 114
Docetaxel plus Ramucirumab Y   48 48 30 18 5 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   44 44 29 15 2 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 25 5 3 1 0 0 05/05/2023 343 109
Capmatinib + Osimertinib + Ramucirumab Y   14 4 2 0 0 0      
Capmatinib + Osimertinib Y   11 1 1 1 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 2 1 1 0 0 11/19/2024 242 80
Amivantamab Hyaluronidase Y   4 2 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 25 18 11 3 1 0 08/08/2024 271 89
Tepotinib + Ramucirumab Y   16 11 7 2 0 0      
Tepotinib Y   9 7 4 1 1 0